Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 8-K (Current Report)
Report Date: November 5, 2025 (Earliest event: November 4, 2025)
Context: This filing reports the results of the Annual Meeting of Stockholders held on November 4, 2025, and references the issuance of a press release regarding operating results for the fiscal quarter ended September 30, 2025, and guidance for the fiscal year ending June 30, 2026.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Actions
Annual Meeting Results (November 4, 2025):
- Attendance: 97.3% of voting power represented (14,543,375 Class A shares and 20,166,034 Class B shares).
- Director Elections: All three Class III Director nominees (Jack C. Bendheim, Alejandro Bernal, E. Thomas Corcoran) were elected to serve until the 2028 annual meeting.
- Executive Compensation: Stockholders approved, on an advisory basis, the compensation of named executive officers.
- Compensation Vote Frequency: Stockholders advised in favor of holding advisory votes on executive compensation every three years.
- Auditor Ratification: Stockholders ratified the selection of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
Guidance, Outlook, and Risks
Guidance and Outlook: The company issued financial guidance for the fiscal year ending June 30, 2026, and reported operating results for the quarter ended September 30, 2025. Specific guidance figures are not detailed in this filing text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text beyond standard disclosures regarding the non-filing status of the press release exhibit.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 financial results and FY2026 guidance figures.
- Verify the voting breakdown for the Class III Director elections to assess shareholder sentiment.
- Confirm the implications of the "every three years" advisory vote frequency on future executive compensation oversight.
- Check the 2025 Proxy Statement for detailed background on the director nominees and executive compensation proposals.